直播时间：2026年3月20日（周五）20:00——21:30

直播平台：

科学网App

https://weibo.com/l/wblive/p/show/1022:2321325278485320171544

（科学网微博直播间链接）

科学网微博

科学网视频号

【内容介绍】

iCANX Talks第261期将于3月20日正式开播，本期特邀浙江大学校长助理、求是讲席教授顾臻带来主题演讲，麦吉尔大学生物医学工程系助理教授陈国军、新南威尔士化学工程学院教授谷子、北京大学集成电路学院教授张海霞担任研讨嘉宾，威斯康星大学麦迪逊分校药学院罗宾逊杰出讲席副教授胡全银主持本场对话。顶尖学者云集，前沿科技碰撞，精彩即将呈现！

【嘉宾介绍】

顾臻

浙江大学

Bioinspired Drug Delivery Cells and Devices

【ABSTRACT】

We have long been interested in the design and delivery of intelligent therapeutics based on bioinspired strategies, particularly through engineered cells and cell-inspired systems. The precise regulation achieved by genetic circuits and mechanical/electronic devices often provides inspiration and stimulates new imagination. In this lecture, I will introduce our lab’s recent innovations and translational efforts in intelligent drug delivery systems that can be triggered by disease-associated physiological and pathological signals. First, I will present biomimetic platforms based on cell-drug conjugates, including platelet-drug conjugate and mast cell-mediated delivery technique for targeted cancer therapy, and cell- /tissue-based drug release systems enabled by “cryogenic inactivation” strategies. In addition, I will discuss progress in glucose-responsive smart insulin and related controlled-release devices, as well as our recent advances in the development of long-acting drug delivery formulations and device-integrated platform technologies. I will also highlight AI technologies for augmenting performance of drug delivery devices.

我们一直对基于仿生策略的工程化细胞与类细胞系统用于智能药物的设计与递释研究很感兴趣，基因线路和器械/电子元件的精准调控往往给人以启迪并激发想象。在本报告中，将介绍课题组目前在能随疾病相关生理、病理信号触发的智能药物递释体系方面的创新与转化。首先，将介绍基于细胞偶联药物的仿生体系，包括用于肿瘤靶向治疗的血小板偶联药物、肥大细胞递药技术、基于“冷冻灭活”技术的细胞及组织释药系统等；另一方面，将讨论能随血糖响应的智能胰岛素及其控释器械方向上的进展，并介绍课题组近年来围绕长效药物递释制剂与器械平台技术的创制，此外，将特别介绍基于人工智能（AI）技术的给药器械。

【BIOGRAPHY】

Dr. Zhen Gu is Qiushi Distinguished Chair Professor and Associate Vice President at Zhejiang University. He also serves as the Director of the National Key Laboratory of Advanced Drug Delivery and Release Systems, and Deputy Director of the Drug Delivery Committee of Chinese Pharmaceutical Association. Dr. Gu was elected to the College of Fellows of the Controlled Release Society (CRS, 2025), Chinese Society for Biomaterials (CSB, 2025), Chinese Biomaterials Academic Advisory Committee of Chinese Academy of Medical Sciences (CAMS, 2024), International Academy of Medical and Biological Engineering (IAMBE, 2021) and American Institute for Medical and Biological Engineering (AIMBE, 2019). Dr. Gu received his B.S. degree in Chemistry and M.S. degree in Polymer Chemistry and Physics from Nanjing University. In 2010, he obtained Ph.D. from the Department of Chemical and Biomolecular Engineering at the University of California, Los Angeles (UCLA). He was a Postdoctoral Associate working with Dr. Robert Langer at MIT and Harvard Medical School. Before he moved to Zhejiang University in 2020, he was a Full Professor in the Department of Bioengineering and Director of the NIH Biotechnology Training in Biomedical Sciences and Engineering Program at UCLA. From 2012 to 2018, he was working in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, where he had been appointed as a Jackson Family Distinguished Professor. Dr. Gu’s group studies controlled drug delivery, biomaterials, drug delivery devices, and cell therapy. As a lead contact, he has published over 200 research papers in high-profile journals, including Cell and Nature. He has also applied over 200 patents that have been licensed to over 10 companies. He is the recipient of the National Natural Science Award (second place) in China (2024), Felix Franks Medal of the Royal Society of Chemistry (2020), Young Investigator Award of Controlled Release Society (2017), Sloan Research Fellowship (2016), Pathway Award of the American Diabetes Association (2015), and MIT Technology Review TR35 (35 Innovators under 35) award (2015). His major inventions include glucose-responsive insulin, transdermal microneedle patch and platelet-drug conjugate, which are under clinical trials. He serves as the Executive Editor of Engineering and Associate Editor of Biomaterials, Nano Research, and Regenerative Biomaterials.

顾臻，浙江大学校长助理、求是讲席教授，国际联合学院院长，金华研究院院长，教育部长江学者，先进药物递释系统全国重点实验室主任，中国医学科学院学术咨询委员会学部委员，中国药学会药剂专业委员会副主任委员，中国生物材料学会常务理事。本科、硕士毕业于南京大学化学化工学院化学系与高分子科学与工程系；2010年于加州大学洛杉矶分校（UCLA）获得工学博士学位；同年博士后获聘于麻省理工学院化工系/Koch癌症综合研究院、哈佛大学医学院；2012-2018年任教于北卡罗莱纳大学教堂山分校/北卡州立大学联合生物医学工程系，获评Jackson Family杰出讲席教授；2018-2020年任UCLA生物工程系正教授，并任生物技术/生物医学与工程培训中心主任。2020年全职回国工作，曾任浙江大学药学院院长（2020-2025）。2019年当选美国医学与生物工程院会士，2021年当选国际医学与生物工程院会士，2024年当选中国医学科学院学术咨询委员会学部委员，2025年当选国际药物控释学会会士、中国生物材料学会会士。曾获国家自然科学奖二等奖、浙江省自然科学奖一等奖、浙江省教学成果奖特等奖、斯隆研究奖、世界青年创新家奖（TR35）、美国糖尿病学会Pathway研究奖等。其研究方向包括生物技术药物递释系统、智能生物材料、药械组合产品、细胞递药策略等，其团队首创了血糖响应性“智能胰岛素贴片”及长效安全胰岛素周制剂，提出了闭路透皮递药系统的新概念；系统拓展了微针释药的应用，并促成其规模化生产；开创性利用血小板及肥大细胞的靶向特性研制了细胞偶联药物，并提出基于细胞器、类器官及机体组织的释药技术。目前以主通讯作者在Cell、Nature等期刊发表/接收学术论文200余篇，转让企业专利100余项，有5项原创新药/技术进入到临床试验阶段。目前担任Engineering期刊学科执行主编，Biomaterials、Nano Research、Regenerative Biomaterials等期刊副主编。